Timmons Patricia, McGill Lakeya S, Aaron Rachel V, Rogers Andrew H, Wegener Stephen T, Campbell Claudia M, Mun Chung Jung
College of Health Solutions, Arizona State University.
Department of Medicine, University of Pittsburgh School of Medicine.
Stigma Health. 2024 Sep 23. doi: 10.1037/sah0000573.
Experiences of discrimination, a notable psychosocial stressor, are considered an important risk factor for problematic opioid use. We examined whether pain severity, pain interference, anxiety, and depressive symptoms are pathways through which discrimination may be associated with increased prescription opioid misuse behaviors among individuals with chronic pain.
A total of 234 participants who reported being prescribed opioids for chronic pain management were included from a parent longitudinal study collected from Amazon's MTurk. Study variables were collected at baseline and 12-month follow-up. Path analyses tested the hypothesized model, with socio-demographic variables and outcomes measured at baseline included as covariates. Mediated effects were examined using percentile bootstrap method.
After controlling for socio-demographic covariates, pain severity, pain interference, anxiety, and depressive symptoms, baseline discrimination was significantly associated with greater prescription opioid misuse behaviors (=.020) at 12 months. Baseline discrimination was also significantly associated with anxiety (<.001) and depressive symptoms (<.001) at 12 months. However, pain severity, pain interference, anxiety, and depressive symptoms were not significantly associated with prescription opioid misuse at 12 months. Mediation analyses indicated no significant effects.
Discrimination may play an important role in prescription opioid misuse behaviors among individuals with chronic pain. Furthermore, discrimination is a risk factor contributing to elevated anxiety and depressive symptoms, with broad clinical implications for individuals coping with chronic pain. However, pain severity, pain interference, anxiety and depressive symptoms did not emerge as underlying mechanisms that link discrimination and prescription opioid misuse. Replication and extension in future studies are warranted.
歧视经历是一种显著的社会心理应激源,被认为是阿片类药物使用问题的重要风险因素。我们研究了疼痛严重程度、疼痛干扰、焦虑和抑郁症状是否是歧视与慢性疼痛患者处方阿片类药物滥用行为增加之间可能存在关联的途径。
从亚马逊的MTurk收集的一项母纵向研究中纳入了总共234名报告因慢性疼痛管理而被开具阿片类药物处方的参与者。在基线和12个月随访时收集研究变量。路径分析检验了假设模型,将基线时测量的社会人口统计学变量和结果作为协变量纳入。使用百分位数Bootstrap方法检验中介效应。
在控制了社会人口统计学协变量、疼痛严重程度、疼痛干扰、焦虑和抑郁症状后,基线时的歧视与12个月时更大的处方阿片类药物滥用行为(β = 0.020)显著相关。基线时的歧视在12个月时也与焦虑(p < 0.001)和抑郁症状(p < 0.001)显著相关。然而,疼痛严重程度、疼痛干扰、焦虑和抑郁症状在12个月时与处方阿片类药物滥用没有显著相关。中介分析表明没有显著影响。
歧视可能在慢性疼痛患者的处方阿片类药物滥用行为中起重要作用。此外,歧视是导致焦虑和抑郁症状升高的风险因素,对慢性疼痛患者具有广泛的临床意义。然而,疼痛严重程度、疼痛干扰、焦虑和抑郁症状并未成为连接歧视和处方阿片类药物滥用的潜在机制。未来研究有必要进行重复和扩展。